Last reviewed · How we verify
Human serum albumin infusion 4% — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Human serum albumin infusion 4% (Human serum albumin infusion 4%) — University Hospital, Strasbourg, France.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human serum albumin infusion 4% TARGET | Human serum albumin infusion 4% | University Hospital, Strasbourg, France | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human serum albumin infusion 4% CI watch — RSS
- Human serum albumin infusion 4% CI watch — Atom
- Human serum albumin infusion 4% CI watch — JSON
- Human serum albumin infusion 4% alone — RSS
Cite this brief
Drug Landscape (2026). Human serum albumin infusion 4% — Competitive Intelligence Brief. https://druglandscape.com/ci/human-serum-albumin-infusion-4. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab